A Phase 3 interventional study of Fingolimod 1.25 mg and Fingolimod 0.5 mg in Relapsing-remitting Multiple Sclerosis, sponsored by Novartis. Completed at 115 sites in 19 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2012-04-11.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one has the largest enrollment, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 1st registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,272 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 142 across the 19 interventional studies. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 19 have an industry lead sponsor. The 5 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis: 1 open now, 4 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 34 studies in Multiple Sclerosis, Relapsing-Remitting by Novartis, this one has the largest enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2006, is one of 5 in phase 3, and was the 1st registered.
Novartis’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Among Novartis’s 34 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria applied to this study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fingolimod 1.25 mg
Drug: Fingolimod 0.5 mg
Drug: Placebo
Patients self-administered fingolimod 1.25 mg capsules orally once daily.
Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Patients self-administered a fingolimod placebo capsule orally once daily.
Estimated Annualized Aggregate Relapse Rate (ARR)
The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.
Time frame: Baseline to end of study (Month 24)
Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS)
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.
Time frame: Baseline to end of study (Month 24)
Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline
The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
Time frame: Baseline to end of study (Month 24)
| Milestone | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo |
|---|---|---|---|
| Started | 429 | 425 | 418 |
| Completed | 332 | 369 | 332 |
| Not completed | 97 | 56 | 86 |
| Withdrew: Withdrawal by subject | 31 | 17 | 28 |
| Withdrew: Adverse event | 22 | 13 | 18 |
| Withdrew: Lack of efficacy | 13 | 6 | 25 |
| Withdrew: Abnormal laboratory value(s) | 20 | 9 | 1 |
| Withdrew: Lost to follow-up | 3 | 5 | 7 |
| Withdrew: Protocol violation | 5 | 5 | 4 |
| Withdrew: Abnormal test procedure result(s) | 2 | 1 | 1 |
| Withdrew: Death | 1 | 0 | 2 |
The ARR is defined as the number of confirmed relapses in a year. A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection. The annualized ARR for each treatment group was the mean of the annualized ARRs for all patients in the group calculated as the total number of confirmed relapses divided by the total number of days on study, multiplied by 365.25.
| Relapses per year | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo |
|---|---|---|---|
| Estimated Annualized Aggregate Relapse Rate (ARR) | 0.16 (0.13 to 0.19) | 0.18 (0.15 to 0.22) | 0.40 (0.34 to 0.47) |
EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) is calculated. Disability progression was determined by the following: One point increase from baseline in patients with baseline EDSS score from 0 to 5.0; or half a point increase in patients with baseline EDSS score of 5.5 or above. A 3-month confirmed disability progression required onset EDSS, 3-month confirming EDSS, and all EDSS in between to meet the disability progression criteria. Percent of free of disability progression was calculated using the Kaplan Meier method.
| Percentage of participants | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo |
|---|---|---|---|
| Percentage of Patients Free of Disability Progression at Month 24 Assessed With the Expanded Disability Status Scale (EDSS) | 83.4 ± 1.87 | 82.3 ± 1.89 | 75.9 ± 2.17 |
The number of new or newly enlarged T2 lesions at Month 24 in comparison to baseline was assessed with T2-weighted magnetic resonance image (MRI) scans. A T2-weighted MRI scan utilizes particular values of the echo time (TE) and the repetition time (TR) parameters of image acquisition. Inflammation and tissue damage are seen as bright areas in T2 images and are often referred to as T2 lesions. T2-weighted MRI scans are a sensitive way to evaluate the brain for demyelinating diseases, such as multiple sclerosis.
| T2 lesions | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo |
|---|---|---|---|
| Number of New or Newly Enlarged T2 Lesions at Month 24 in Comparison With Baseline | 2.5 ± 5.52 | 2.5 ± 7.19 | 9.8 ± 13.17 |
Collected over 24 Months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod 1.25 mg | — | 51/429 (11.9%) | 346/429 (80.7%) |
| Fingolimod 0.5 mg | — | 43/425 (10.1%) | 355/425 (83.5%) |
| Placebo | — | 56/418 (13.4%) | 323/418 (77.3%) |
| Event | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo |
|---|---|---|---|
| BradycardiaCardiac disorders | 3/429 | 4/425 | 1/418 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/429 | 4/425 | 2/418 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/429 | 0/425 | 3/418 |
| AbortionPregnancy, puerperium and perinatal conditions | 0/429 | 0/425 | 3/418 |
| Macular oedemaEye disorders | 3/429 | 0/425 | 0/418 |
| Multiple sclerosis relapseNervous system disorders | 3/429 | 2/425 | 1/418 |
| Myocardial infarctionCardiac disorders | 0/429 | 0/425 | 2/418 |
| Non-cardiac chest painGeneral disorders | 0/429 | 2/425 | 2/418 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/429 | 0/425 | 2/418 |
| Chest painGeneral disorders | 0/429 | 2/425 | 0/418 |
| Event | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 112/429 | 115/425 | 115/418 |
| HeadacheNervous system disorders | 113/429 | 107/425 | 96/418 |
| Upper respiratory tract infectionInfections and infestations | 62/429 | 73/425 | 72/418 |
| InfluenzaInfections and infestations | 40/429 | 55/425 | 41/418 |
| DiarrhoeaGastrointestinal disorders | 40/429 | 50/425 | 30/418 |
| Back painMusculoskeletal and connective tissue disorders | 45/429 | 49/425 | 28/418 |
| Alanine aminotransferase increasedInvestigations | 49/429 | 42/425 | 16/418 |
| FatigueGeneral disorders | 46/429 | 48/425 | 45/418 |
| Urinary tract infectionInfections and infestations | 21/429 | 34/425 | 47/418 |
| CoughRespiratory, thoracic and mediastinal disorders | 37/429 | 43/425 | 34/418 |
| Age Continuous(years) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 37.4 ± 8.91 | 36.6 ± 8.77 | 37.2 ± 8.60 | 37.1 ± 8.76 |
| Age, Customized(participants) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| <18 years | 1 | 0 | 0 | 1 |
| 18 -30 | 107 | 120 | 97 | 324 |
| 31-40 | 147 | 162 | 165 | 474 |
| 41-55 | 174 | 143 | 156 | 473 |
| Sex: Female, Male(Participants) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 295 | 296 | 298 | 889 |
| Male | 134 | 129 | 120 | 383 |
| Duration of multiple sclerosis since first symptoms(Years) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.4 ± 6.86 | 8.0 ± 6.60 | 8.1 ± 6.35 | 8.2 ± 6.60 |
| Number of relapses in last 2 years(relapses) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 1.5 ± 0.81 | 1.5 ± 0.76 | 1.4 ± 0.73 | 1.5 ± 0.77 |
| Expanded Disability Status Scale (EDSS)(Units on a scale) | Fingolimod 1.25 mg | Fingolimod 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 2.41 ± 1.36 | 2.30 ± 1.29 | 2.49 ± 1.29 | 2.40 ± 1.32 |
Showing the first 100 of 115 sites across 19 countries. Choose a country and city above to see the rest.
The record gives a start of Jan 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Relapsing-Remitting →